Redeye reiterates its neutral stance to Northbaze on the back of a slightly better than expected Q1-report. Even though the company achieved a breakeven result on EBITDA-level in the quarter, we expect the following two quarters to be tough. The risk is still high in the case and we remain cautious, as the company’s loss-absorption buffer is limited.